Deficient HRR, primarily due to BRCA1/BRCA2 mutations, non-BRCA HRR gene alterations, and epigenetic changes, influences tumor behavior and enhances sensitivity to platinum-based chemotherapy and PARPi [3,9]. This evidence concerns the gene BRCA1 and neoplasm.